HUTCHMED (China) Limited (AIM:HCM)
230.00
+10.00 (4.55%)
Apr 17, 2026, 8:22 AM GMT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,796 employees as of December 31, 2025. The number of employees decreased by 15 or -0.83% compared to the previous year.
Employees
1,796
Change (1Y)
-15
Growth (1Y)
-0.83%
Revenue / Employee
226.92K GBP
Profits / Employee
189.02K GBP
Market Cap
1.89B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,796 | -15 | -0.83% |
| Dec 31, 2024 | 1,811 | -177 | -8.90% |
| Dec 31, 2023 | 1,988 | -37 | -1.83% |
| Dec 31, 2022 | 2,025 | 265 | 15.06% |
| Dec 31, 2021 | 1,760 | 480 | 37.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Haleon | 24,535 |
| Hikma Pharmaceuticals | 9,400 |
| Allergy Therapeutics | 584 |
| Animalcare Group | 201 |
| ECO Animal Health Group | 200 |
| Shield Therapeutics | 63 |
| Venture Life Group | 43 |
| Chill Brands Group | 11 |
HUTCHMED (China) News
- 8 days ago - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 - GlobeNewsWire
- 24 days ago - HUTCHMED Initiates And Doses First Patient In Phase III Trial Of HMPL-760 For R/R DLBC Lymphoma - Nasdaq
- 25 days ago - HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China - GlobeNewsWire
- 4 weeks ago - HUTCHMED (China) Ltd (HCM) Shares Up 3.67% on Mar 16 - GuruFocus
- 5 weeks ago - HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ... - GuruFocus
- 5 weeks ago - HUTCHMED (China) Ltd (HCM) Trading 4.6% Higher on Mar 11 - GuruFocus
- 5 weeks ago - Hutchmed (HCM) Withdraws Tazverik from China Amid U.S. Market Recall - GuruFocus
- 5 weeks ago - HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China - GlobeNewsWire